Advanced Biotherapy, Battelle to collaborate on anthrax, plague therapies

Los Angeles, California-based Advanced Biotherapy (OTCBB: ADVB) has entered into an initial Memorandum of Understanding (MOU) with Battelle to develop and use monoclonal antibodies to treat humans and animals exposed to anthrax and plague. The purpose of the MOU is to form a cooperative relationship which will allow the two companies to participate in the Initiatives for Proliferation Prevention (IPP) projects of the U.S. Department of Energy (DoE), specifically regarding the development of anti-cytokine therapy as a treatment for anthrax and plague affecting humans and animals. The two companies will also collaborate on using anti-cytokine therapy in treating other autoimmune conditions.

-read more about Advanced-Battelle collaborative effort at Advanced Web site; read more about DoE IPP at DoE Web site